Royal Bank of Canada Reduces Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Royal Bank of Canada cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 7.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 155,104 shares of the medical research company's stock after selling 11,691 shares during the quarter. Royal Bank of Canada owned 0.30% of Charles River Laboratories International worth $28,632,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Optiver Holding B.V. purchased a new stake in Charles River Laboratories International during the 4th quarter valued at about $37,000. GeoWealth Management LLC raised its position in Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after purchasing an additional 190 shares during the last quarter. Pilgrim Partners Asia Pte Ltd bought a new position in Charles River Laboratories International during the 4th quarter valued at approximately $48,000. Tortoise Investment Management LLC raised its position in Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after purchasing an additional 115 shares during the last quarter. Finally, Huntington National Bank raised its position in Charles River Laboratories International by 120.6% during the 4th quarter. Huntington National Bank now owns 300 shares of the medical research company's stock valued at $55,000 after purchasing an additional 164 shares during the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on CRL shares. Mizuho lowered their price target on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. Redburn Atlantic raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and lowered their price target for the company from $188.00 to $182.00 in a research report on Friday. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and upped their price target for the company from $155.00 to $175.00 in a research report on Tuesday, March 4th. JPMorgan Chase & Co. lowered their price target on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research report on Thursday, February 20th. Finally, Robert W. Baird upped their price target on Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the company. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of "Hold" and a consensus target price of $171.85.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president now directly owns 19,513 shares in the company, valued at $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Up 1.5%

CRL traded up $2.09 during trading on Tuesday, hitting $138.82. 800,873 shares of the company's stock traded hands, compared to its average volume of 993,202. The company's 50 day simple moving average is $131.30 and its two-hundred day simple moving average is $162.22. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15. The stock has a market capitalization of $6.82 billion, a price-to-earnings ratio of 925.47, a PEG ratio of 4.54 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, beating the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. During the same period last year, the business posted $2.27 EPS. The company's revenue was down 2.7% compared to the same quarter last year. Analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).